Navigation Links
Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
Date:11/16/2010

NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2010 /PRNewswire/ -- Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.  These data, presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC 2010) and American Association of Pharmaceutical Sciences (AAPS) Annual Meeting, provide a mechanistic explanation for the observed absence of nephrotoxicity in human clinical testing of both compounds to date.  Nephrotoxicity is a significant dose-limiting factor for several comparable therapies.

Chimerix is applying its powerful PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to existing antiviral compounds to create new chemical entities with improved pharmaceutical attributes.  The PIM Conjugate Technology is used to modify a drug molecule so that it mimics a naturally occurring phospholipid.  The lipid mimic can then utilize natural uptake pathways enabling oral bioavailability and altering drug distribution profiles. Chimerix's lead clinical candidate CMX001 applies Chimerix's PIM Conjugate Technology to the antiviral agent cidofovir, while the second clinical stage compound, CMX157, is the company's proprietary lipid conjugation of tenofovir.  Both cidofovir and tenofovir are known to cause nephrotoxicities, and the severity of nephrotoxicities associated with cidofovir in particular have substantially limited its use.  Chimerix has created CMX001 and CMX157 with the intent of minimizing this serious side effect while enhancing drug bioavailability and antiviral activity.  

The study reported at the World Congress was designed to evaluate whether CMX001 and CMX157 are substrates of human O
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
8. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
9. New forms of highly efficient, flexible nanogenerator technology
10. Verenium to Present at Jefferies 10th Global Clean Technology Conference
11. Voluntary initiatives, regulation and nanotechnology oversight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Basel in Switzerland have succeeded in observing the ... the first time. These extremely weak spectra offer ... and may also contribute to the development of ... published in the scientific journal Nature Physics ... between matter and light, is probably the most ...
(Date:9/20/2014)... 20, 2014 HealthTronics, Inc. ... interventional radiology products and services, has signed a ... Clinicon Corporation for its high precision ... of minimally invasive, mobile, surgical technology—offering more choices ... the agreement, HealthTronics will make available Clinicon’s FDA-cleared ...
(Date:9/19/2014)... NEW YORK, September 18, 2014 Scientists at NYU ... boost dramatically the efficiency of the process for turning ... three well-known compounds, including vitamin C. Using the new ... stem cells obtained from adult skin cells by more ... their technique is efficient and reliable, and thus should ...
(Date:9/19/2014)... 19, 2014 Biotech companies make ... emerging drug systems and advanced Laboratory Instrumentation. Companies in ... (NYSE: BDX ), Thermo Fisher Scientific Inc. ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ...
Breaking Biology Technology:Uncovering the forbidden side of molecules 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7
... - From less than 1 million to 600 ... growth in the past 10 years. , ,From the ... job, providing better tools for finding, filtering and presenting ... decade on the Web and also looking forward to ...
... Madison, Wis. - Stratatech Corporation , a UW ... from the National Institute on Aging, for the development of ... wounds such as diabetic, venous stasis and pressure ulcers, which ... estimated that in the United States alone, millions of people ...
... Madison, Wis. Pierce Biotechnology , a ... BioSurfaces of Madison, Wis., to distribute GenTel's trademarked ... use of GenTel technology in developing new protein arrays ... specifically designed for protein-array applications, including the profiling of ...
Cached Biology Technology:Internet Scout celebrates 10 years on web, eyes new project launch 2
(Date:9/22/2014)... New Haven, Conn. Yale University researchers are studying ... pulmonary fibrosis, a respiratory disease in which scars develop ... treatment uses a microRNA mimic, miR-29, which is delivered ... only blocked pulmonary fibrosis, it reversed fibrosis after ... in the journal EMBO Molecular Medicine . , ...
(Date:9/22/2014)... molecular cog in a plant,s biological clock one ... on temperature. , Transcription factors, or genetic switches, drive ... such as light, rain, soil quality, or even animals ... has isolated one, called FBH1, that reacts to temperature ... while in keeping it on a consistent track. , ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Genetic switch regulates a plant's internal clock based on temperature 2
... Recognizes Leadership in Technology and Innovation in Global ... LMT ) has been named the ... Frost and Sullivan, recognizing the Corporation,s leadership in ... of customers. Frost and Sullivan based the award ...
... The Centre for Genomic Regulation (CRG) in Barcelona, Spain ... by Genomatix Software GmbH. , GGA comprises purpose built ... software providing a complete solution for the analysis of ... genome. "In regards to the machine, I love ...
... 4, 2009 The incidence of pneumothorax (PTX), or collapsed ... has been reported to range from 13 50 percent, ... In people, PTX is reported to be the most preventable ... ultrasound has been infrequently used as a non-invasive, point-of-care imaging ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CRG buys Genomatix' Next Generation Sequencing analysis solution 2Novel veterinary procedure detecting life-threatening injuries touted 2
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... Faster speeds, highest precision, more ... flexible concept: this is the definition of ... few years nucleic acid research has been ... capabilities required of PCR Systems. To ...
... genomics-based research with S. aureus, Sigma-Genosys has developed ... primers to amplify all open reading frames (ORFs) ... are included to amplify ORFs that are unique ... S. aureus. The ORFmer set contains primers to ...
Biology Products: